

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/537,401	11/21/2005	Hiroshi Tsuchita	· Q88294	1465
23373 7	10/27/2006		EXAMINER	
SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W.			TSAY, MARSHA M	
SUITE 800 WASHINGTON, DC 20037		ART UNIT	PAPER NUMBER	
		1656		

DATE MAILED: 10/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

10/537,401					
	TSUCHITA ET AL.				
Examiner	Art Unit				
Marsha M. Tsay	1656				
pears on the cover sheet with the c	orrespondence address				
ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONEI	J. ely filed the mailing date of this communication. C (35 U.S.C. § 133).				
Responsive to communication(s) filed on This action is FINAL. 2b) This action is non-final.					
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
Ex parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
4)⊠ Claim(s) <u>1-13 and 16</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
S)⊠ Claim(s) <u>1-13 and 16</u> is/are rejected.					
Claim(s) is/are objected to.					
r election requirement.					
er.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
caminer. Note the attached Office	Action or form PTO-152.				
s have been received. s have been received in Application rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Paper No(s)/Mail Da 5) Notice of Informal P	te				
	Marsha M. Tsay Dears on the cover sheet with apply and will expire SIX (6) MONTHS from sheet application to become ABANDONED and the sheet of this communication, even if timely filed sheet action is non-final. The cover sheet				

Claims 14-15 are canceled. Claims 1-13, 16 are pending and currently under examination.

Priority: The benefit date is December 2, 2003, for the purpose of prior art.

Specification

The disclosure is objected to because of the following informalities: the priority data needs to be updated.

Appropriate correction is required.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 2-13, 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Brantman (US 4687782; IDS). Brantman teaches diet supplements comprising a combination of amino acids, i.e. branched amino acids, to promote muscle adaptation to strenuous exercise. In example 1, Brantman teaches a composition comprising leucine, isoleucine, valine, glutamine, and a whey protein, i.e. casein, soy protein, lactalbumin (col. 5 lines 60-65; claims 2-4, 7-10, 13). Brantman further teaches a method of supplementing the diet of an athlete comprising administering a solution comprising leucine, isoleucine, valine, glutamine, and a whey protein; and having the

Application/Control Number: 10/537,401

Art Unit: 1656

athlete drink the solution (col. 6 lines 42-53; claim 16). In col. 4 lines 45-50, Brantman also teaches numerical ranges for the amino acids used in the composition: leucine (20-45 parts), isoleucine (15-40 parts), valine (15-40 parts), glutamine (10-30 parts) (claims 5-6, 11-12), wherein the relative proportions of the amino acids are preferably within 20% of the recited ranges (col. 5 lines 20-25).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brantman (US 4687782; IDS). The teachings of Brantman is outlined above. Brantman further teaches a composition comprising: an amino acid mixture consisting essentially of carnitine, isoleucine, leucine, valine, glutamine, and a whey protein, i.e. casein, soy protein, lactalbumin (col. 7 lines 30-50), adapted for use with water as a diet supplement for facilitating the adaptation of skeletal muscle and liver to a program of strenuous exercise. Brantman does not specifically teach a composition consisting of leucine, isoleucine, valine, glutamine, and a whey protein.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the teachings of Brantman and formulate a composition consisting of isoleucine, leucine, valine, glutamine, and a whey protein, i.e. casein (claim 1). The motivation to do so is also given by Brantman, which teaches a composition comprising essentially of the

Art Unit: 1656

branched amino acids, isoleucine, leucine, valine, glutamine, and a whey protein, such as casein, can be formulated into a diet supplement to promote muscle adaptation to strenuous exercise.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marsha M. Tsay whose telephone number is 571-272-2938. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Kathleen Kerr can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

> VSHIPOURI, PH.D. RIMARY EXAMINER

October 23, 2006